

Original Research Article

**Urinary Tract Infection Associated with Carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae***

**ABSTRACT**

**Background and Objectives:**

Carbapenemase producing bacteria are super bugs that make UTI difficult to treat with drug of last resort such as carbapenem and other antibiotic thus limiting the treatment options. Carbapenemase production is increasing in clinical isolates of *E. coli* and *K. pneumoniae*, their potential to spread widely among patients necessitates molecular analysis of Urinary Tract Infection associated with Carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae*

**Methodology**

A total of twelve (12) non-repeated clinical isolate of *Escherichia coli* (E1, E2, E3, E4, E5, E6, E7) and *Klebsiella pneumoniae* (K8, K9, K10, K11, K12) were collected from selected patient diagnosed with Urinary tract infection at Alex Ekwueme Federal University Hospital Teaching Hospital (AE-FEUTHA). *Escherichia coli* and *Klebsiella pneumoniae* were further confirmed using standard routine microbiological Technique for isolation and identification. *Escherichia coli* and *Klebsiella pneumoniae* strains were further screen for carbapemase producing gene by PCR specific primer.

**Result**

PCR analysis with carbapenemase gene specific primer revealed the presence and predominat of *blaKPC* in *Escherichia coli* and *Klebsiella pneumoniae* accounted 12(100 %) followed by *blaNDM* 11(91.7 %), *blaIMP* 7(58.3 %) and *blaVIM* 2(16.7) as the least carbapemase producing gene in *Escherichia coli* and *Klebsiella pneumoniae*. *blaKPC* was highly predominant in *Escherichia coli* 7(58.3 %) followed by *blaNDM* 6(50.0 %) and *blaIMP* 5(41.7 %) while both *blaOXA* and *blaVIM* (16.7 %) were the least detected carbapenemase gene. *Klebsiella pneumoniae* harbor high proportion of *blaNDM* and *blaKPC* both recording 5(41.7 %) followed by *blaOXA* and *blaIMP* both recording 2(16.7 %) but no *blaVIM* gene

**Conclusion**

The findings of this study highlight the occurrence of carbapemase-producing gene in *Escherichia coli* and *Klebsiella pneumoniae* in UTI. Since this gene are carried on the bacteria plasmid there is a tendency of cross-species dissemination over time. Therefore, it should be noted that carbapemase-producing reservoirs in healthcare workers, patients, or the hospital environment may be a principle mode of spread in nosocomial outbreaks.

**Keywords:** Urinary Tract Infection, Carbapenemase-producing, *Escherichia coli*, *Klebsiella pneumoniae*

## 1. INTRODUCTION

A carbapenemase producing *Escherichia coli* or *Klebsiella pneumoniae* are bacteria that is resistant to imipenem, meropenem, doripenem, or ertapenem in susceptibility testing or has a carbapenemase gene [1]. In 2017, the World Health Organization designated carbapenemase producing *E. coli* and *Klebsiella pneumoniae* as 'critical' and 'high priority pathogens' in 2017 [2]. Since then, carbapenem producing *Escherichia coli* and *Klebsiella pneumoniae* is a growing concern worldwide [3, 4] due to rapid evolution and spread of carbapenemase producing genotype e.g., New Delhi metallo- $\beta$ -lactamase (*blaNDM*), Imipenemases (*blaIMP*), Verona integron Metallo-beta-lactamase

(*blaVIM*), Oxacillinase (*blaOXA*) and *Klebsiella pneumoniae* carbapenemase (*blaKPC*) which are increasingly being reported among health care associated complicated UTIs owing to their ability to truncate the action of carbapenem and other beta-lactam antibiotics [4, 5, 6]. Urinary Tract Infections (UTIs) are infectious diseases commonly caused by enterobacteriae such *Escherichia coli* and *Klebsiella pneumoniae* [4, 7, 8]. This bacteria invade and colonize any part of the urinary tract [4, 9] producing symptoms such as fever, burning sensations while urinating, Lower Abdominal Pain (LAP), itching, blister and ulcer formation in the genital area, genital and suprapubic pain, and pyuria are generally determined by the age of the person infected and the location of the infected urinary tract. UTIs are common bacterial infections that affect approximately 150 million people worldwide each year, posing a significant financial burden on the community and health-care system [6]. The prevalent and rapidly evolving carbapenemase gene (*bla* NDM, *bla* IMP, *bla* VIM, *blaOXA* and *blaKPC*) from *Escherichia coli* and *Klebsiella pneumoniae* make UTI difficult to treat with drug of last resort such as carbapenem thus limiting the treatment options. These resistance genes containing bacteria are super bugs and are termed as carbapenemase producing *Escherichia coli* and *Klebsiella pneumoniae* challenging the empiric treatment of UTI worldwide. The worldwide distribution of *E. coli* and *K. pneumoniae* harboring carbapenemase genes is a serious threat, and due to carbapenemase production, carbapenemase gene is progressively spreading among clinical isolates of *E. coli* and *K. pneumoniae*. As these strains are serious threat to public health, their potential to spread widely amongst patients require molecular evaluation.

## 2. MATERIALS AND METHODS

### 2.1 Characterization of *Escherichia coli* and *Klebsiella pneumoniae*

Clinical isolate of *Escherichia coli* (E1, E2, E3, E4, E5, E6, E7) and *Klebsiella pneumoniae* (K8, K9, K10, K11, K12) were collected from selected patient diagnosed with Urinary tract infection at Alex Ekwueme Federal University Hospital Teaching Hospital (AE-FEUTHA). All the information obtained from the studied subjects was coded to maintain confidentiality and in accordance with the World Medical Association (WMA) declaration of Helsinki on the principles for medical research [10, 11]. The twelve clinical isolate of *Escherichia coli* and *Klebsiella pneumoniae* were further confirmed using standard routine microbiological Technique [12, 13].

### 2.2 Molecular Screening for Carbapenemase Genes Using Polymerase Chain Reaction (PCR)

#### 2.2.1 DNA Extraction

Genomic DNA Extraction of *Escherichia coli* and *Klebsiella pneumoniae* was performed using ZR Fungal/Bacterial DNA Miniprep™ (Manufactured by Zymo research, cat number: D6005) kit according to the manufacturer's protocol. Exactly 2 ml of bacterial cells broth was added to a ZR Bashing™ Lysis tube and 750 µg lysis solutions was added to it. This was secured in a bead fitted with 2 ml tube holder assembly and processed at a maximum speed for 5 minutes. The ZR Bashing Bead™ lysis tube was centrifuged at > 10,000 x g for 1 minute. Up to 400 µg of supernatant was transferred to a Zymo-Spin™ IV Filter in a collection tube and centrifuged at 7,000 x g for 1 minute. Exactly 1,200 µg of fungal/bacterial DNA Binding Buffer was added to the filtrate in the collection tube. Exactly 800 µl of the mixture from step 5 was transferred to a Zymo-spin™ IIC Column in a collection tube and centrifuged at 10,000 x g for 1 minute. The flow through from the collection tube was discarded. Then 200 µl DNA Pre-washed buffer was added to the Zymo-Spin™ IIC Column in a new tube collection and centrifuged at 10,000 x g for 1 minute. About 200 µg of Fungal/Bacterial DNA Buffer was added to the Zymo-Spin™ IIC Column and centrifuged at 10,000 x g for 1 minute. The Zymo-Spin™ IIC Column was transferred to a clean 1.5 ml micro-centrifuge tube and 100 µl (35 µl minimum) DNA was added directly to the column matrix. Centrifuge was done at 10,000 x g for 30 seconds to elute DNA [11, 14].

#### 2.2.2 Electrophoresis for DNA and PCR

Exactly 1 g of agarose was measured (for DNA) and 2 g of agarose for PCR products. Agarose powder was mixed with 100 ml 1xTAE in a microwave flask. This was microwaved for 1-3 min until agarose is completely dissolved. The agarose solution was allowed to cool to about 50 °C. Then 10 µg EZ vision DNA stain was added. The agarose was poured into a gel tray with the well comb in place. The newly poured gel was placed at 4 °C for 10-15 mins until it has completely solidified [11, 14].

#### 2.2.3 Loading Samples and Running an Agarose Gel.

A loading Buffer was added to each DNA sample of PCR products. Once it got solidified the agarose gel was placed into the gel box (electrophoresis unit). The gel box was filled with 1xTAE buffer until the gel was covered. A molecular weight ladder was carefully loaded into the first lane of gel and the samples were carefully loaded into the additional wells of gel. The gel was run at 80-150 V for about 1-1.5 h. The power was turned off, and the electrodes disconnected from the power source and then the gel was carefully removed from the gel box. The DNA fragments or PCR fragments was visualized under UV trans-illuminator [15, 16].

#### 2.2.4 PCR Mix Components

The PCR mix components was made up of 12.5  $\mu$ l of Taq 2 x Master Mix from New England Biolabs (M0270); 1  $\mu$ l each of 10 $\mu$ M forward and reverse primer (Invitrogen, U. S. A™) (Table 1); 2  $\mu$ l of DNA template and then made up with 8.5  $\mu$ L Nuclease free water. The PCR reactions was executed as previously described by Edemekong *et al.* [14].

#### 2.2.4 Cycling Conditions

Initial denaturation at 94° C for 5 mins, followed by 36 cycles of denaturation at 94° C for 30 secs, annealing at 55° C for 30 second and elongation at 72° C for 45 seconds. Then a final elongation step at 72° C for 7 minutes and hold temperature at 10° C. Initial denaturation at 94° C for 5mins, followed by 40 cycles of denaturation at 94° C for 30sec, annealing at 37° C for 30secs and elongation at 72° C for 45 sec. Followed by a final elongation step at 72° C for 7 minutes and hold temperature at 10° C forever [17].

Table 1: The following Primer Sequences was use for detection of Cabapenemase resistance genes [15, 16].

Primers	Sequence (5'-3'),	Amplicon size (bp)	Annealing Temperature
BlaKPC	F: CGTCTAGTTCTGCTGTCTTG R: CTTGTCATCCTTGTTAGGCG	500	56° C
blaOXA	F:GCGTGGTTAAGGATGAACAC R: CATCAAGTTCAACCCAACCG	550	56° C
BlaIMP	F:CTACCGCAGCAGAGTCTTTGC R: ACAACCAGTTTTGCCTTACC	232	45° C
blaNDM	F:GCAGCTTGTCGGCCATGCGGGC R: GGTCGCGAAGCTGAGCACCGCAT	800	52° C
BlaVIM	F:AAAGTTATGCCGCACTCACC R: TGCAACTTCATGTTATGCCG	250	56° C

### 3. RESULT

#### Molecular detection of Carbapenemase encoding gene in UTI patient harboring *Escherichia coli* and *Klebsiella pneumoniae*

The proportion of *blaKPC* in *Escherichia coli* and *Klebsiella pneumoniae* accounted 12(100 %) followed by *blaNDM* 11(91.7 %), *blaIMP* 7(58.3 %) and *blaVIM* 2(16.7) as the least CR gene in *Escherichia coli* and *Klebsiella pneumoniae*. *blaKPC* was highly predominant in *Escherichia coli* 7(58.3 %) followed by *blaNDM* 6(50.0 %) and *blaIMP* 5(41.7 %) while both *blaOXA* and *blaVIM* (16.7 %) were the least detected carbapenemase gene. *Klebsiella pneumoniae* harbor high proportion of *blaNDM* and *blaKPC* both recording 5(41.7 %) followed by *blaOXA* and *blaIMP* both recording 2(16.7 %) while no *blaVIM* gene was detected as shown in Table 2.

**Table 2:** Molecular detection of Carbapenemase encoding gene in UTI patient harboring *Escherichia coli* and *Klebsiella pneumoniae*

Carbapenemase Class	Genes	Enterobacteria (n=12)		
		E1-7 (%)	K8-12 (%)	Frequency (%)
A	<i>blaKPC</i>	7(58.3)	5(41.7)	<b>12(100)</b>
B	<i>blaIMP</i>	5(41.7)	3(25.0)	<b>7(66.7)</b>
B	<i>blaVIM</i>	2(16.7)	0(0.0)	<b>2(16.7)</b>
B	<i>blaNDM</i>	6(50.0)	5(41.7)	<b>11(91.7)</b>
D	<i>blaOXA</i>	2(16.7)	2(16.7)	<b>4(33.3)</b>

**Key:** n-Number of isolate, *blaKPC*-*Klebsiella pneumoniae* carbapenemase, *blaIMP*-Imipenemases, *blaVIM*-Verona integron Metallo-beta-lactamase, *blaNDM*-New Delhi Metallo-beta-lactamase, *blaOXA*-Oxacillinase

#### 4. DISCUSSION

The molecular detection of carbapenemase resistance genes among the isolates in this study revealed that the *blaKPC* in *Escherichia coli* and *Klebsiella pneumoniae* accounted for 12(100 %) followed by *blaNDM* 11(91.7 %), *blaIMP* 7(58.3 %) and *blaVIM* 2(16.7) as the least CR gene in *E. coli* and *K. pneumoniae*. The plasmid-encoded KPC enzyme was first identified in a *K. pneumoniae* isolate from North Carolina, USA [18]. Since 2001, these isolates have spread across the USA, with reports of KPC-producers across 38 states [19]. Although KPC-producers are now being identified at an alarming rate across Europe, facilitated mostly by clonal dissemination, to the best of our knowledge there is no published report of *blaKPC*-positive isolates from this area of study (Abakaliki) but in Maiduguri, northeast Nigeria and in two Chinese studies, *blaKPC* has been reported as the predominant carbapenemase gene [16, 20, 21].

The *blaNDM* 11(91.7 %) was the second most predominant carbapenem gene, despite the fact that NDM-1 bearing gene is increasingly reported worldwide, NDM-1 has been most commonly identified in *E. coli* and *K. pneumoniae* [6, 21, 22, 23, 24, 25] as evidence in this study. This study inferred that the frequent switch of predominant carbapenemase genotype might result from introduction of those strains from different sources (like some regions, animals or food) with different popular carbapenemase genes, or transformation of some mobile elements that carried carbapenemase genes between species [26, 27, 28]. Although the driving mechanism for this situation remains unclear, it further highlights the importance of long-term active resistance surveillance of CR-isolate in community and hospital setting. Although existing literature highlight India and Pakistan being considered to be the main reservoir for NDM-producing isolates which were detected in this study, it has been suggested that the Middle East region might be a secondary reservoir for the spread of *blaNDM*-1 isolates as there is a high frequency of population movement between Saudi Arabia and the Indian subcontinent [29, 30, 31, 32]. This study speculate that population movement where *blaKPC* and *blaNDM* is endemic and was first identified, might explain the high occurrence of isolates with *blaKPC* resistance gene in this setting, although the absence of data on patient travel history to those endemic area precludes any firm conclusions being drawn.

Although *blaOXA* recorded 4(33.3 %). OXA is mostly known to be frequently detected in *K. pneumoniae* and *E. coli*, but can also occur in other Enterobacteriales. The production of OXA is one of the main mechanisms of carbapenem resistant in most bacteria. This finding correspond with Alizadeh *et al.* [33] who reported percentage of carbapenemase genes in *K. pneumoniae*; *blaOXA*-like (78%) while different *E. coli* clones have successfully emerged in the world; examples are *E. coli* O15:K52:H1-D of sequence type 393 (ST393), *E. coli* ST131, and *E. coli* ST38, which is characterized by the production of the OXA  $\beta$ -lactamase and is related to strains of the Mediterranean basin countries [34, 35]. The role of *blaOXA* strain in UTI in this study can't be underestimated but virulence has been linked to the presence of *bla<sub>OXA-48</sub>* in clinical *E. coli* and *K. pneumoniae* isolates. Several studies reported on clinical isolates with an unusual high lethality in murine infection models as well as the presence of genes associated with virulence or host colonization, but the specific role of OXA-48 had not been addressed [36, 37, 38].

To the best of our knowledge this study tends to be the first to report the present of *blaVIM* 2(16.7) in *E. coli* while isolate positive for the *blaVIM* gene has been found by other researchers [20, 23, 39, 40, 41] and in one study it was located on an Inc11 plasmid of a novel sequence type (ST 297) by multilocus sequence typing [42]. Since this gene are carried on plasmid there is a tendency of cross-species dissemination over time.

Although, *blaIPM* 66.7 % was reported in this finding, notably this genes are not commonly reported among *E. coli* and *K. pneumoniae* but the co-existence of Amber class A, B and D are known to confer resistance to oxyiminocephalosporins (ceftriaxone and ceftazidime) and cephamycins (cefoxitin), and transfer of the resistance has been confirmed by transconjugation [43, 44, 45]. Therefore, it should be noted that Carbapenemase reservoirs in healthcare workers, patients, or the hospital environment may be a principle mode of spread in nosocomial outbreaks.

#### 5. CONCLUSION

This finding echoes a successfully emergence of carbapenemase producing genes in *E. coli* and *K. pneumoniae* associated UTI, which is characterized by the production of the *blaKPC*, *blaNDM*, *blaIMP* and *blaVIM*. Although, *blaVIM* gene was absence in *K. pneumoniae*, the virulence role of carbapenemase producing genes in UTI in this study can't be underestimated but as could be linked to the persistence of UTI among patients. The detection of Carbapenemase gene call for prompt epidemiological surveillance and preventive strategies to limit the spread of

these carbapenemase resistant genetic determinant and the need for antibiotic susceptibility testing of available antibiotic agent .

**CONSENT**

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

**ETHICAL APPROVAL**

In compliance with international standard or university standard written ethical approval has been collected and preserved by the author (s).

UNDER PEER REVIEW

## REFERENCES

1. Center for Disease Control and Prevention (CDC). Catheter-Associated Urinary Tract Infections. *Report Series*. 2017; 13:1-45
2. World Health Organization (WHO). Global Priority List of Antibiotic-resistant Bacteria to guide Research, discovery, and development of new antibiotics <https://www.who.int/medicines/publications/WHO-PPL-Short>. 2017
3. Nordmann, P. Current Situation on Spread of Metallo- $\beta$ -lactamases in Enterobacteriaceae [Abstract C1-1331]. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston: *American Society for Microbiology*. 2010.
4. Suwaiba M, Dadah AJ, Sanusi SB. Prevalence of Carbapenem resistant *Escherichia coli* and *klebsiella pneumoniae* in urine samples of Patients Attending Selected General Hospitals within Kaduna Metropolis. *Sci. World J.* 2020; 15(4):23-67.
5. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, eds. Principles and Practice of Infectious Diseases, 8th Edition, Philadelphia, USA: Elsevier Saunders. 2014:886-913.
6. Nasir F, Khan MI, Kashif S, Uddin F, Naseer A, Masood S. Prevalence of ESBLs secreting and carbapenem-resistant *E. coli* from urinary tract infection. *Rawal Med J.* 2021; 46:3-23.
7. Tenney J, Hudson N, Alnifaigy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review, *Saudi Pharm J.* 2018; 26:678–684.
8. Ngong IN, Fru-Cho J, Yung MA, Akoachere JKT. Prevalence, Antimicrobial Susceptibility Pattern and Associated Risk Factors for Urinary Tract Infections in Pregnant Women Attending ANC in some Integrated Health Centers in the Buea Health District. *BMC Pregnancy Childbirth.* 2021; 21:673-674.
9. Al Yousef SA, Younis S, Farrag E, Moussa HS, Bayoumi FS, Ali AM. Clinical and Laboratory Profile of Urinary Tract Infections Associated with Extended Spectrum  $\beta$ -Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae*. *Annals of Clin and Laboratory Sci.* 2016; 46(4):393-400.
10. World Medical Association (WMA) Declaration of Helsinki. Ethical principles for Medical Research involving Human Subjects. Note of Clarification on paragraph 30 by the WMA General Assembly, Tokyo. 2004;9-10.
11. Peter IU, Emelda NC, Chukwu EB, Ngwu JN, Uzoeto HO, Moneth EC, Stella AO, Edemekong CI, Uzoamaka EP, Nwuzo AC, Iroha IR. Molecular Detection of Bone Sialoprotein-Binding Protein (*bbp*) Genes among Clinical Isolates of Methicillin Resistant *Staphylococcus aureus* from Hospitalized Orthopedic Wound Patients. *Asian J Orthopaedic Res.* 2022, 8(3): 1-9.
12. Edemekong, CI, Iroha IR, Thompson, MD, Okolo, IO., Uzoeto HO, Ngwu JN, Mohammed ID, Chukwu EB, Nwuzo AC, Okike BM, Okolie SO, Peter IU. Phenotypic Characterization and Antibigram of Non-Oral Bacteria Isolates from Patients Attending Dental Clinic at Federal College of Dental Technology and Therapy Medical Center Enugu. *Int J Pathog Res.* 2022; 11(2): 7-19.
13. Iroha IR, Orji JO, Onwa NC, Nwuzo AC, Okonkwo EC, Ibiam EO, Nwachi AC, Afuikwa FN, Agah VM, Ejikeugwu EPC, Agumah NB, Moses IB, Ugbo E, Ukpai EG, Nwakaeze E A, Oke B, Ogbu L and Nwunna E. Microbiology Practical Handbook. (Editor; Ogbu. O), 1<sup>st</sup> Edition. Charlieteximage Africa (CiAfrica Press), 2019; Pp:344.
14. Edemekong CI, Uzoeto HO, Mbong EO, Ikusika BA, Didiugwu, CM, Ngwu JN, NseAbasi PL, Ntekpe ME, Mohammed ID, John-Onwe BN, Alagba EE, Obodoechi IF, Joseph OV, Ogbonna IP, Ubom IJ, Peter IU (2022). Molecular Characterization and Bioassay of Soil *Actinomycetes* Strains on Multidrug Resistant Bacteria. *IOSR J Biotechnol Biochem.* 2022; (1):6-11.
15. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global Dissemination of Carbapenemase-Producing *Klebsiella pneumoniae*: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. *Front Microbiol.* 2016; 7:895.

16. Wang B, Pan F, Wang C, Zhao W, Sun Y, Zhang T, Shi Y, Zhang H. Molecular Epidemiology of Carbapenem-resistant *Klebsiella pneumoniae* in a Paediatric Hospital in China. *Int J Infect Dis.* 2020; 93:311–319.
17. Ferreira RL, da Silva BCM, Rezende GS, Nakamura-Silva R, Pitondo-Silva A, Campanini EB, Brito MCA, da Silva EML, Freire CCM, Cunha AF, Pranchevicius MC. High Prevalence of Multidrug-Resistant *Klebsiella pneumoniae* Harboring Several Virulence and Beta-Lactamase Encoding Genes in a Brazilian Intensive Care Unit. *Front Microbiol.* 2019; 9:31-98.
18. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD. Novel carbapenem-hydrolyzing  $\beta$ -lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *J Antimicrob Agent Chemother.* 2001; 45:1151–1161.
19. Chen LF, Anderson DJ, Paterson DL. Overview of the Epidemiology and the Threat of *Klebsiella pneumoniae* carbapenemases (KPC) Resistance. *Infect Drug Resist.* 2012; 5:133–41.
20. Mohammed Y, Zailani SB, Onipede AO. Characterization of KPC , NDM and VIM type carbapenem resistance Enterobacteriaceae from north eastern Nigeria. *J Bio Med.* 2015; 3:100–7
21. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data from a Longitudinal Large-scale CRE Study in China (2012–2016). *Clin Infect Dis J.* 2018; 67 (2):196–205.
22. Olalekana A, Onwugambab F, Iwalokunc B, Mellmann A, Beckerb K, Schaumburg F. High Proportion of Carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* among Extended-spectrum  $\beta$ -lactamase-producers in Nigerian Hospitals. *J Glob Antimicrob Resist.* 2020; 21:8–12.
23. Aminu A, Daneji IM, Yusuf MA, Jalo RI, Tsiga-Ahmed FI, Yahaya M. Carbapenem-resistant Enterobacteriaceae Infections among Patients Admitted to Intensive Care Units in Kano, Nigeria. *Sahel Med J.* 2021; 24:1-9.
24. Thapa A, Upreti MK, Bimali NK, Shrestha B, Sah AK, Nepal K, Dhungel B, Adhikari S, Adhikari N, Lekhak B, Rijal KR. Detection of NDM Variants (*bla*NDM-1, *bla*NDM-2, *bla*NDM-3) from Carbapenem-Resistant *Escherichia coli* and *Klebsiella pneumoniae*: First Report from Nepal. *Infect and Drug Resist.* 2022; 15 4419–4434.
25. Zhang Q, Lv L, Huang X, Huang Y, Zhuang Z, Lu J. Rapid Increase in Carbapenemase-producing Enterobacteriaceae in Retail Meat Driven by the Spread of the Carrying IncX3 Plasmid in China from 2016 to 2018. *J Antimicrob Agent Chemother.* 2019; 63(8):56-78.
26. Marques C, Belas A, Aboim C, Cavaco-Silva P, Trigueiro G, Gama LT. Evidence of Sharing of *Klebsiella pneumoniae* Strains between Healthy Companion Animals and Cohabiting Humans. *J Clin Microbiol Infect Dis.* 2019; 57(6):234-456.
27. Zhang F, Xie L, Wang X, Han L, Guo X, Ni Y. Further Spread of *bla* NDM-5 in Enterobacteriaceae via IncX3 plasmids in Shanghai, China. *Front Microbiol.* 2016; 7:424-425.
28. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B. Epidemiology of Carbapenem-resistant Enterobacteriaceae Infections: Report from the China CRE Network. *J Antimicrob Agent Chemother.* 2018; 62(2):23-45.
29. Alhazmi W, Al-Jabri A, Al-Zahrani I. The Molecular Characterization of Nosocomial Carbapenem-Resistant *Klebsiella pneumoniae* Co-Harboring *bla*NDM and *bla*OXA-48 in Jeddah. *Microbiol Res.* 2022; 13:753–764.
30. Shibl A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. The emergence of OXA-48- and NDM-1-positive *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. *Int J Infect Dis.* 2013; 17:1130–1133
31. Shibl A, Senok A, Memish Z. Infectious Diseases in the Arabian Peninsula and Egypt. *J Clin Microbiol Infect Dis.* 2012; 18: 1068–80.
32. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis.* 2011; 17:1791–8.
33. Alizadeh N, Rezaee MA, Kafil HS, Hasani A, Barhaghi MHS, Milani M, Sefidan FY, Memar MY, Lalehzadeh A, Ghotaslou R. Evaluation of Resistance Mechanisms in Carbapenem-Resistant Enterobacteriaceae. *Infect Drug Resist.* 2020; 13 1377–1385

34. Potron A, Poirel L, Rondinaud E, Nordmann, P. Intercontinental Spread of OXA-48  $\beta$ -lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. *EuroSurveillance*. 2013; 18:20549.
35. Poirel L, Carbonnelle E, Bernabeu S, Gutmann L, Rotimi V, Nordmann P. Importation of OXA-48-producing *Klebsiella pneumoniae* from Kuwait. *J Antimicrob Agent Chemother*. 2012; 67:2051–2052.
36. Beyrouthy R, Robin F, Cougnoux A, Dalmasso G, Darfeuille-Michaud A, Mallat H (2013). Chromosome-mediated OXA-48 Carbapenemase in Highly Virulent *Escherichia coli*. *J Antimicrob Agent Chemother*. 2013; 68:1558–1561.
37. Beyrouthy R, Robin F, Dabboussi F, Mallat H, Hamze M, Bonnet R. Carbapenemase and Virulence Factors of Enterobacteriaceae in North Lebanon between 2008 and 2012: Evolution via Endemic Spread of OXA-48. *J Antimicrob Agent Chemother*. 2014; 69:2699–2705.
38. de Toro M, Fernandez J, Garcia V, Mora A, Blanco J, De La Cruz F. Whole genome sequencing, Molecular Typing and *in vivo* Virulence of OXA-48-producing *Escherichiacoli* isolates including *ST131 H30-Rx*, *H22* and *H41* Subclones. *J Scientific Report*, 2017; 7:12103-12109.
39. Hashemizadeh Z, Hosseinzadeh Z, Azimzadeh N, Motamedifar M. Dissemination Pattern of Multidrug Resistant Carbapenemase Producing *Klebsiellapneumoniae* Isolates Using Pulsed-Field Gel Electrophoresis in Southwestern Iran. *Infect Drug Resist*. 2020; 13:921–929.
40. Tian D, Pan F, Wang C, Sun Y, Zhang H. Resistance Phenotype and Clinical Molecular Epidemiology of Carbapenem-resistant *Klebsiella pneumoniae* among Pediatric Patients in Shanghai. *Infect and Drug Resist*. 2018; 11:1935–43.
41. Saavedra SY, Bernal JF, Montilla-Escudero, E., Arévalo, S. A., Andrés Prada, D., Valencia, M. F., Moreno, J., Hidalgo, A. M., García-Vega, Á. S., Abrudan, M., Argimón, S., Kekre, M., Underwood, A., Aanensen, D. M., Duarte, C., Donado-Godoy, P and NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance (2021). Complexity of Genomic Epidemiology of Carbapenem-Resistant *Klebsiella pneumoniae* Isolates in Colombia Urges the Reinforcement of Whole Genome Sequencing-Based Surveillance Programs. *Clinical Infectious Diseases*, 73(4):290–9.
42. Murugan MS, Sinha DK, Vinodh Kumar OR, Yadav AK, Pruthvishree BS, Vadhana P, Nirupama KR, Bhardwaj M, Singh BR. Epidemiology of Carbapenem Resistant *Escherichia coli* and First Report of blaVIM Carbapenemases Gene in Calves from India. *Epidemiol Infect*. 2019; 147:159, 1–5.
43. Lee K, Yong D, Choi YS, Yum JH, Kim J M, Woodford N, Livermore DM, Chong Y. Reduced Imipenem Susceptibility in *Klebsiella pneumoniae* Clinical Isolates with Plasmid-mediated CMY-2 and DHA-1 Beta-lactamases Co-mediated by Porin Loss. *Int J Antimicrob Agents*. 2007; 29: 201- 206.
44. Ding H, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, Wang A, Deng Q, Zhang H, Wang C. The Prevalence of Plasmid-mediated AmpC beta-lactamases among Clinical Isolates of *Escherichia coli* and *Klebsiella pneumoniae* from Five Children's Hospitals in China. *Euro J Clin Microbiol Infect Dis*. 2008; 27:915-921.
45. Yamada Y, Ishii Y, Kouyama Y, Katho M, Odashiro R, Yamahata K, Tateda K, Yamaguchi K, Suwabe A (2009) Characterization of *Klebsiella pneumoniae* producing SHV-12 and DHA-1 beta-lactamases Accompanied by Carbapenem Resistance during Hospitalization in a Chronic Care Ward in Japan. *J Chemother*. 2008; 21:445-447.